Oncology Focus Areas:
Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}

      • This website is for UK Healthcare Professionals only

      This promotional website is for UK Healthcare Professionals involved in the management of haematological malignancies. Adverse event reporting information can be found below.

      Venclyxto logo
      VENCLYXTO CLL PRESCRIBING INFORMATION
      VENCLYXTO GB SUMMARY OF PRODUCT CHARACTERISTICS
      VENCLYXTO NI SUMMARY OF PRODUCT CHARACTERISTICS

      UK-VNCCLL-230491. Date of preparation: February 2024.

       

       

      Page coming soon.

       

       

       

      You are advised to read the Prescribing Information and Summary of Product Characteristics to evaluate patient suitability for VENCLYXTO.

      VENCLYXTO PRESCRIBING INFORMATION
      VENCLYXTO SUMMARY OF PRODUCT CHARACTERISTICS (GB)
      VENCLYXTO SUMMARY OF PRODUCT CHARACTERISTICS (NI)

      UK-VNCCLL-230507. Date of preparation: April 2024.

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores. Adverse events should also be reported to AbbVie on [email protected]

       

      This website is for UK Healthcare Professionals only

      UK-ABBV-230225. Date of preparation June 2023. This website has been developed and funded by AbbVie Ltd.

      © 2023 AbbVie Ltd. All rights reserved. Registered Number: 08004972 England.